Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer
10.3971/j.issn.1000-8578.2023.23.0102
- VernacularTitle:PD-1/PD-L1抑制剂在HIV/AIDS合并癌症患者中的应用进展
- Author:
Changgang DENG
1
;
Wei ZHANG
;
Yanyu SUN
;
Qisui LI
;
Wei HUANG
;
Jing YUAN
Author Information
1. Department of Infectious Disease, Chongqing Public Health Medical Center, Chongqing 400036, China
- Publication Type:Research Article
- Keywords:
PD-1/PD-L1 inhibitor;
AIDS;
HIV;
Cancer
- From:
Cancer Research on Prevention and Treatment
2023;50(9):924-928
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has become a common means of cancer treatment. In immunotherapy, PD-1/PD-L1 inhibitors have significant efficacy. Cancer and various opportunistic infections are common complications in patients with AIDS. Owing to the special immune situation of these patients, AIDS is regarded as an exclusion standard in most clinical trials for cancer immunotherapy, conferring immunotherapy difficulty in treating patients with AIDS. The popularity of effective antiretroviral drugs has prolonged the lifetime of people with AIDS. Therefore, exploiting the opportunity of using immunotherapy in AIDS with cancer is urgent.
